Publications by authors named "Francesca Musto"
Background & Aims: Glecaprevir/Pibrentasvir (GLE/PIB) has been approved by the European Medicine Agency (EMA) and by the US Food and Drug Administration (US-FDA) for the treatment of children and adolescents from 3 years of age with chronic hepatitis C virus (CHC) infection. The aim of this study was to confirm the real-world effectiveness and safety of GLE/PIB in children and adolescents (3 to < 18 years old) with CHC.
Methods: This prospective, multicentre study involved 11 Italian centres.
Article Synopsis
- The study analyzed the management and outcomes of Hepatitis C virus (HCV) in children at a Milan hospital over a 25-year period, noting a focus on new treatments and liver stiffness measurements.
- Out of 57 pediatric patients, 14% cleared the virus on their own, while 58% received treatment with successful outcomes, indicated by undetectable HCV RNA levels post-therapy.
- The research highlights that while many children show normal liver stiffness measurements before age 12, those with abnormal results experienced significant improvement after treatment with direct-acting antiviral agents, emphasizing the need for further studies on liver elastography in this population.
Anemia is one of the most frequent extra-intestinal manifestations of inflammatory bowel disease. Insidious onset, variability of symptoms and lack of standardized screening practices may increase the risk of underestimating its burden in children with IBD. Despite its relevance and peculiarity in everyday clinical practice, this topic is only dealt with in a few documents specifically for the pediatric field.
View Article and Find Full Text PDFBackground: Current data on dual biologic therapy in children are limited. This multicenter study aimed to evaluate the effectiveness and safety of dual therapy in pediatric patients with inflammatory bowel disease (IBD).
Methods: A retrospective study from 14 centers affiliated with the Pediatric IBD Interest and Porto Groups of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition.
Article Synopsis
- - Anemia is a common issue among children newly diagnosed with inflammatory bowel disease (IBD), with a study finding that 64% of such patients presented with anemia upon diagnosis.
- - This research included 76 children from a larger group and monitored their responses to sucrosomial iron (SI) treatment over a 12-month period, finding that 88% showed improvement in their anemia, half of whom improved within just 3 months.
- - The study concluded that SI is both a safe and effective treatment for anemia related to pediatric IBD, with no serious adverse effects reported during the follow-up.
Background: Exclusive enteral nutrition (EEN) is the first choice to induce remission and promote mucosal healing in pediatric Crohn's disease (CD). However, full adherence to EEN treatment may be problematic for children with CD.
Methods: The goal of the current multicenter retrospective study was to define predictive factors of nonadherence to treatment and nonremission at the end of induction treatment.
Mucopolysaccharidosis-plus syndrome (MPS-PS) is a novel autosomal recessive disorder caused by a mutation in the gene. This syndrome presents with typical symptoms of mucopolysaccharidosis, as well as congenital heart defects, renal, and hematopoietic system disorders. To date, twenty-four patients have been described.
View Article and Find Full Text PDF